Trial reportFrontiers in immunology2018
Robust Humoral and Cellular Immune Responses to Pertussis in Adults After a First Acellular Booster Vaccination.
Trial report in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- Flow Cytometric Assessment of Pertactin- and Tetanus Toxoid-Specific B-Cell Kinetics After Tdap Booster Vaccination in Healthy Adults.Vaccines · 2026Article
- CD4+ T-cell immunity toDiscover immunity · 2026Review
- Evaluation of immune responses to Tdap booster during pregnancy in women who received whole cell or acellular pertussis vaccines during childhood.Emerging microbes & infections · 2025Article
- Booster Injection with Birch Pollen Extract Activates B-Cellular Memory Responses in Patients Having Completed Allergen Immunotherapy.European journal of immunology · 2025Article
- A literature review and evidence-based evaluation of the Dutch national immunisation schedule yield possibilities for improvements.Vaccine: X · 2024Review
- Antiviral responses induced by Tdap-IPV vaccination are associated with persistent humoral immunity to Bordetella pertussis.Nature communications · 2024Article
- Quantitative mechanistic model reveals key determinants of placental IgG transfer and informs prenatal immunization strategies.PLoS computational biology · 2023Article
- Article
- Post-vaccination serum cytokines levels correlate with breakthrough influenza infections.Scientific reports · 2023Article
- Article
- Vaccine-Induced Cellular Immunity againstVaccines · 2021Review
- Review
- Circulation of pertussis and poor protection against diphtheria among middle-aged adults in 18 European countries.Nature communications · 2021Article
- Influenza vaccine-induced human bone marrow plasma cells decline within a year after vaccination.Science (New York, N.Y.) · 2020Article
- Antibody responses to Bordetella pertussis and other childhood vaccines in infants born to mothers who received pertussis vaccine in pregnancy - a prospective, observational cohort study from the United Kingdom.Clinical and experimental immunology · 2019Observational
- Th1/Th17 polarization persists following whole-cell pertussis vaccination despite repeated acellular boosters.The Journal of clinical investigation · 2018Article
- Adaptive immune response to bordetella pertussis during vaccination and infection: emerging perspectives and unanswered questions.Expert review of vaccinesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: To reduce the pertussis disease burden, nowadays several countries recommend acellular pertussis (aP) booster vaccinations for adults. We aimed to evaluate the immunogenicity of a first adult aP booster vaccination at childbearing age. Methods: In 2014, healthy adults aged 25-29 years ( Results: Upon booster vaccination, the IgG levels specific to all Tdap vaccine antigens were significantly increased. After an initial rapid decline in the first year, PT-IgG antibody decay was limited (15%) in the second year post-booster. The duration of a median level of PT-IgG ≥20 IU/mL was estimated to be approximately 9 years. Vaccine antigen-specific memory B- and T-cell numbers increased and remained at high levels although a significant decline was observed after 4 weeks post-booster. However, Th1, Th2, and Th17 cytokine production remained above pre-booster levels for 2 years. Conclusion: The Tdap booster vaccination in wP-primed Dutch adults induced robust long-term humoral and cellular immune responses to pertussis antigens. Furthermore, PT-IgG levels are predicted to remain above the presumed protective cut-off for at least 9 years which might deserves further attention in evaluating the current recommendation to revaccinate women during every new pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.